entinostat has been researched along with Peritoneal Carcinomatosis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Gupta, VG | 1 |
Hirst, J | 1 |
Petersen, S | 1 |
Roby, KF | 1 |
Kusch, M | 1 |
Zhou, H | 1 |
Clive, ML | 1 |
Jewell, A | 1 |
Pathak, HB | 1 |
Godwin, AK | 1 |
Wilson, AJ | 1 |
Crispens, MA | 1 |
Cybulla, E | 1 |
Vindigni, A | 1 |
Fuh, KC | 1 |
Khabele, D | 1 |
1 other study available for entinostat and Peritoneal Carcinomatosis
Article | Year |
---|---|
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; Carcinoma, Ovari | 2021 |